ROCKVILLE, Md.--(BUSINESS WIRE)--
(NASDAQ:GLYC) today announced that pre-clinical
research demonstrating the potential of two of its drug candidates,
GMI-1271 and GMI-1359, against multiple myeloma will be shared via an
oral presentation at the American
Association for Cancer Research (AACR) Annual Meeting 2017
. The company and its collaborators at Washington
University in St. Louis
will highlight data on GMI-1271
an antagonist of E-selectin, and GMI-1359
a dual antagonist of E-selectin and CXCR4, showing anti-cancer activity
in preclinical models of multiple myeloma.
The research demonstrated that:
In cell culture, GMI-1271 and, to a greater extent GMI-1359, reduced
multiple myeloma cell adhesion to stromal cells and inhibited
chemotaxis of multiple myeloma cells toward conditioned media.
The presence of GMI-1271 or GMI-1359 reduced stroma-induced drug
resistance of multiple myeloma cells to carfilzomib and lenalidomide.
In a preclinical model of multiple myeloma, combination therapy of
GMI-1271 and lenalidomide profoundly delayed tumor growth.
Combination therapy of carfilzomib with GMI-1271 or GMI-1359 prolonged
survival of mice with multiple myeloma over treatment with carfilzomib
"Our results show a strong effect on cancer cells in combination with
chemotherapy and importantly, are supportive of our ongoing Phase 1
clinical studies in multiple myeloma of GMI-1271 as well as our study of
GMI-1359 in multiple cancers," said John
Magnani, Ph.D., GlycoMimetics Senior Vice President and Chief Scientific
Officer. "These results complement data from other preclinical
studies and continue to build the rationale for our on-going clinical
programs with both compounds."
Details of the AACR presentation include:
Abstract #5005—Muz, B.B., et al. "Inhibition of E-Selectin or
E-selectin together with CXCR4 re-sensitizes multiple myeloma to
treatment." Tuesday, April 4, 3:00-5:00 p.m. ET.
The AACR Annual Meeting 2017 takes place from April 1 to 5, at the
Walter E. Washington Convention Center. Meeting abstracts are available
at AACR's website.
GMI-1271 is currently being evaluated in an ongoing Phase 1/2 clinical
trial as a potential treatment for acute myeloid leukemia (AML) and in a
Phase 1 clinical trial in multiple myeloma. GMI-1359 is now in a Phase 1
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease. GlycoMimetics' most advanced drug
candidate, rivipansel, a pan-selectin antagonist, is being developed for
the treatment of vaso-occlusive crisis in sickle cell disease and is
being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug
candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidates, GMI-1271 and GMI-1359. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including the availability and timing of data from ongoing clinical
trials, the uncertainties inherent in the initiation of future clinical
trials, whether interim results from a clinical trial will be predictive
of the final results of the trial or results of early clinical trials
will be indicative of the results of future trials, expectations for
regulatory approvals, availability of funding sufficient for
GlycoMimetics' foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect the
availability or commercial potential of GlycoMimetics' drug candidates
and other factors discussed in the "Risk Factors" section of
GlycoMimetics' Annual Report on Form 10-K that was filed with the U.S.
Securities and Exchange Commission on February 29, 2016, and other
filings GlycoMimetics makes with the Securities and Exchange Commission
from time to time. In addition, the forward-looking statements included
in this press release represent GlycoMimetics' views as of the date
hereof. GlycoMimetics anticipates that subsequent events and
developments may cause its views to change. However, while GlycoMimetics
may elect to update these forward-looking statements at some point in
the future, GlycoMimetics specifically disclaims any obligation to do
so, except as may be required by law. These forward-looking statements
should not be relied upon as representing GlycoMimetics' views as of any
date subsequent to the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006700/en/
Jamie Lacey-Moreira, 410-299-3310
Source: GlycoMimetics, Inc.
News Provided by Acquire Media